Group 1 - The Hong Kong Stock Connect innovative drug sector is experiencing a significant rally, with Ascentage Pharma-B leading with a nearly 6% increase, and several other stocks like Kelun-B and 3SBio rebounding over 4% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) is fully invested in innovative drug R&D companies and saw a trading increase of up to 2% in the afternoon session, with a transaction volume exceeding 340 million yuan [1] - The ETF has attracted over 129 million yuan in net subscriptions during recent dips, indicating strong buying interest [1] Group 2 - The ESMO 2025 annual meeting will take place from October 17-21 in Berlin, where multiple Chinese innovative drug companies are expected to announce breakthrough clinical research results in areas such as kidney and lung cancer [3] - The Federal Reserve's dovish stance suggests a potential interest rate cut in October, which may create a favorable environment for the Chinese pharmaceutical sector [3] - Recent BD transactions, such as the one involving Innovent Biologics with a total value exceeding 2 billion USD, indicate a busy end-of-year period for global innovative drug product licensing collaborations [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the first ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively focuses on innovative drug companies without including CXO [4] - As of the end of September, the fund size of the ETF is 1.806 billion yuan, with an average daily trading volume of 493 million yuan, making it the largest and most liquid ETF in its category [4] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [6]
全球重磅会议ESMO进入倒计时，高弹性港股通创新药ETF（520880）冲高2%！三生制药、亚盛医药-B强势领衔